Terns Pharmaceuticals (TERN) announced that the FDA granted breakthrough therapy designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals Gains FDA Breakthrough Status for TERN-701
- Oppenheimer downgrades Terns Pharmaceuticals to Perform following Merck deal
- Terns Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
- Merck announces expiration of HSR waiting period to acquire Terns Pharmaceuticals
- Terns Pharmaceuticals downgraded to Market Perform from Outperform at Leerink